Lerociclib dihydrochloride is primarily used in the treatment of certain types of cancer, particularly hormone receptor-positive breast cancer. It functions as a CDK4/6 inhibitor, which helps to halt the proliferation of cancer cells by interfering with their cell cycle progression. This makes it a valuable component in combination therapies, often paired with hormone therapies to enhance efficacy. Its application is significant in clinical settings where targeted treatment is crucial for improving patient outcomes and managing advanced or metastatic cancer stages. Ongoing research continues to explore its potential in other cancer types and therapeutic combinations.